Skip to main content

J&J Schizophrenia Drug Faces FDA Delay

The regulator asked for additional data on paliperidone palmitate, an investigational once-monthly intramuscular injection for schizophrenia.

Johnson & Johnson

(JNJ)

said late Tuesday that the Food and Drug Administration asked it for additional data before it will approve its paliperidone palmitate, an investigational once-monthly intramuscular injection for schizophrenia.

The company, which said regulators will not require any additional studies, is currently evaluating the letter and will work with the agency to resolve any outstanding questions.

Johnson & Johnson shares closed down 9 cents at $70.71, and were down 6 cents more in recent post-market trading.